pyrazolone and Colitis

Alterations of discoidin domain receptor1 (DDR1) may lead to increased production of inflammatory cytokines, making DDR1 an attractive target for inflammatory bowel disease (IBD) therapy. A scaffold-based molecular design workflow was established and performed by integrating a deep generative model, kinase selectivity screening and molecular docking, leading to a novel DDR1 inhibitor compound

Topics: Animals; Anti-Inflammatory Agents; Colitis; Deep Learning; Dextran Sulfate; Discoidin Domain Receptor 1; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Molecular Structure; Protein Kinase Inhibitors; Pyrazolones; Pyridazines